Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia

ABSTRACT

Serious bleeding and thrombotic complications are frequent in acute promyelocytic leukemia (APL) and are major causes of morbidity and mortality. Microparticles (MP) have been used to study the risk and pathogenesis of thrombosis in many malignant disorders. To date, from published articles, this approach had not been applied to APL. In this article, the hemostatic dysfunction in this disorder is briefly reviewed. A study design to address this problem using MP is described. MP bearing tissue factor, profibrinolytic factors (tissue plasminogen activator and annexin A2), and the antifibrinolytic factor plasminogen activator inhibitor type 1 were measured using flow cytometry. The cellular origin of the MP was identified by specific cell surface markers. Comparison of the various populations of MP was made between samples collected at the time of diagnosis with those collected at molecular remission. Preliminary data suggest that this approach is feasible.

KEYWORDS

Acute promyelocytic leukemia - bleeding - thrombosis - microparticles - tissue factor; annexin A2

REFERENCES

• 1 Wang Z Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable.  Blood. 2008;  111(5) 2505-2515
• 2 Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future.  Curr Opin Hematol. 2009;  16(2) 84-91
• 3 Falanga A, Rickles F R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.  Best Pract Res Clin Haematol. 2003;  16(3) 463-482
• 4 Kwaan H C, Wang J, Boggio L N. Abnormalities in hemostasis in acute promyelocytic leukemia.  Hematol Oncol. 2002;  20(1) 33-41
• 5 Tallman M S, Kwaan H C. Intravascular clotting activation and bleeding in patients with hematologic malignancies.  Rev Clin Exp Hematol. 2004;  8(1) E1
• 6 Tallman M S, Hakimian D, Kwaan H C, Rickles F R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.  Leuk Lymphoma. 1993;  11(1–2) 27-36
• 7 Vardiman J W, Thiele J, Arber D A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.  Blood. 2009;  114(5) 937-951
• 8 de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.  Nature. 1990;  347(6293) 558-561
• 9 Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment [review].  Hematology(Am Soc Hematol Educ Program. 2006;  156-161, 514
• 10 Licht J D. Acute promyelocytic leukemia—weapons of mass differentiation.  N Engl J Med. 2009;  360(9) 928-930
• 11 Grimwade D, Mistry A R, Solomon E, Guidez F. Acute promyelocytic leukemia: a paradigm for differentiation therapy.  Cancer Treat Res. 2009;  145 219-235
• 12 Nasr R, Guillemin M C, Ferhi O et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.  Nat Med. 2008;  14(12) 1333-1342
• 13 Rego E M, He L Z, Warrell Jr R P, Wang Z G, Pandolfi P P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.  Proc Natl Acad Sci U S A. 2000;  97(18) 10173-10178
• 14 Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.  J Clin Oncol. 2009;  27(4) 504-510
• 15 Sirulnik A, Melnick A, Zelent A, Licht J D. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.  Best Pract Res Clin Haematol. 2003;  16(3) 387-408
• 16 Melnick A, Licht J D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.  Blood. 1999;  93(10) 3167-3215
• 17 Rego E M, Ruggero D, Tribioli C et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.  Oncogene. 2006;  25(13) 1974-1979
• 18 Mueller B U, Buerger A U, Solenthaler M et al. Pleural tumors as sole primary manifestation of acute promyelocytic leukemia.  Ann Oncol. 2006;  17(4) 722-723
• 19 Guibal F C, Alberich-Jorda M, Hirai H et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.  Blood. 2009;  114(27) 5415-5425
• 20 Park D J, Vuong P T, de Vos S, Douer D, Koeffler H P. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays.  Blood. 2003;  102(10) 3727-3736
• 21 Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.  Leukemia. 2000;  14(4) 722-726
• 22 Neame P B, Soamboonsrup P, Leber B et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants.  Am J Hematol. 1997;  56(3) 131-142
• 23 Rizzatti E G, Portieres F L, Martins S L, Rego E M, Zago M A, Falcão R P. Microgranular and t(11;17)/PLZF-RARalpha variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARalpha gene rearrangement.  Am J Hematol. 2004;  76(1) 44-51
• 24 Sanz M A, Grimwade D, Tallman M S et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.  Blood. 2009;  113(9) 1875-1891
• 25 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.  Blood. 1990;  75(11) 2112-2117
• 26 Stein E, McMahon B, Kwaan H, Altman J K, Frankfurt O, Tallman M S. The coagulopathy of acute promyelocytic leukaemia revisited.  Best Pract Res Clin Haematol. 2009;  22(1) 153-163
• 27 Jácomo R H, Melo R A, Souto F R et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines.  Haematologica. 2007;  92(10) 1431-1432
• 28 Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.  Br J Haematol. 2000;  108(4) 689-695
• 29 de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.  Blood. 2008;  111(7) 3395-3402
• 30 Kwaan H C. Double hazard of thrombophilia and bleeding in leukemia.  Hematology Am Soc Hematol Educ Program. 2007;  151-157
• 31 Tallman M S, Abutalib S A, Altman J K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.  Semin Thromb Hemost. 2007;  33(4) 330-338
• 32 Escudier S M, Kantarjian H M, Estey E H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.  Leuk Lymphoma. 1996;  20(5-6) 435-439
• 33 Goldschmidt N, Gural A, Ben Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia.  Leuk Lymphoma. 2003;  44(8) 1433-1437
• 34 Breccia M, Avvisati G, Latagliata R et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.  Leukemia. 2007;  21(1) 79-83
• 35 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia—a single center experience in 34 patients.  Thromb Res. 2005;  116(2) 109-114
• 36 Polliack A. Acute promyelocytic leukemia with disseminated intravascular coagulation.  Am J Clin Pathol. 1971;  56(2) 155-161
• 37 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79(3) 543-553
• 38 Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79(2) 534-535
• 39 Watanabe R, Murata M, Takayama N Keio Hematology-Oncology Cooperative Study Group (KHOCS) et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia.  Thromb Haemost. 1997;  77(4) 641-645
• 40 Dombret H, Scrobohaci M L, Ghorra P et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7(1) 2-9
• 41 Tallman M S, Lefèbvre P, Baine R M et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
• 42 Bennett B, Booth N A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.  Br J Haematol. 1989;  71(4) 511-517
• 43 Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.  Blood. 1991;  77(9) 1949-1957
• 44 Avvisati G, ten Cate J W, Sturk A, Lamping R, Petti M G, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.  Br J Haematol. 1988;  70(1) 43-48
• 45 Falanga A, Iacoviello L, Evangelista V et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid.  Blood. 1995;  86(3) 1072-1081
• 46 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4).  Blood. 1996;  87(2) 613-617
• 47 Drake T A, Ruf W, Morrissey J H, Edgington T S. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line.  J Cell Biol. 1989;  109(1) 389-395
• 48 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine.  Biochemistry. 1986;  25(14) 4007-4020
• 49 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115(2) 382-391
• 50 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
• 51 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
• 52 Kruithof E K. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.  Thromb Haemost. 2008;  100(6) 969-975
• 53 Hultman K, Tjärnlund-Wolf A, Fish R J et al. Retinoids and activation of PKC induce tissue-type plasminogen activator expression and storage in human astrocytes.  J Thromb Haemost. 2008;  6(10) 1796-1803
• 54 Shah M D, Bergeron A L, Dong J F, López J A. Flow cytometric measurement of microparticles: pitfalls and protocol modifications.  Platelets. 2008;  19(5) 365-372
• 55 Berckmans R J, Neiuwland R, Böing A N, Romijn F P, Hack C E, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.  Thromb Haemost. 2001;  85(4) 639-646
• 56 Sanz M A, Lo Coco F, Martín G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.  Blood. 2000;  96(4) 1247-1253
• 57 Willekens F L, Werre J M, Kruijt J K et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors.  Blood. 2005;  105(5) 2141-2145
• 58 Dasgupta S K, Abdel-Monem H, Niravath P et al. Lactadherin and clearance of platelet-derived microvesicles.  Blood. 2009;  113(6) 1332-1339
• 59 Furie B, Furie B C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation.  Trends Mol Med. 2004;  10(4) 171-178
• 60 Deregibus M C, Cantaluppi V, Calogero R et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.  Blood. 2007;  110(7) 2440-2448